Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$266 Mln
Revenue (TTM)
$48 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.2
Industry P/E
--
EV/EBITDA
-1.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
53,228,300
CFO
$-1,032.99 Mln
EBITDA
$-1,045.46 Mln
Net Profit
$-1,425.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
| 70.1 | 0.4 | 109.2 | 4.2 | -24.0 | -- | -- |
|
BSE Sensex*
| 3.8 | 3.4 | 6.9 | 9.7 | 15.4 | 21.9 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
2seventy bio (TSVT)
| -30.9 | -54.4 | -63.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
2seventy bio (TSVT)
|
5.0 | 266.1 | 48.4 | -4.1 | -164.5 | -1.9 | -- | 1.2 |
| 49.3 | 7,705.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.2 | 3.8 | |
| 101.1 | 6,567.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.2 | |
| 142.5 | 6,923.8 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 57.0 | 10,643.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.4 | |
| 44.5 | 12,380.9 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.7 | 5.8 | |
| 52.9 | 6,410.0 | 1,084.3 | 485.4 | 57.0 | 103.8 | 13.8 | 13.3 | |
| 306.7 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 27.3 | 9,614.4 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 122.7 | 11,976.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41 | 4.7 |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell... product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Address: 60 Binney Street, Cambridge, MA, United States, 02142 Read more
President & Director
Mr. Nick Leschly
President & Director
Mr. Nick Leschly
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 2seventy bio Inc (TSVT) stood at $ 521 Mln as on 31-Mar-25
The share price of 2seventy bio Inc (TSVT) is $5.00 (NASDAQ) as of 19-May-2025 09:30 EDT. 2seventy bio Inc (TSVT) has given a return of -23.96% in the last 3 years.
2seventy bio Inc (TSVT) has a market capitalisation of $ 266 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of 2seventy bio Inc (TSVT) is 1.24 times as on 16-May-2025, a 43% discount to its peers’ median range of 2.19 times.
Since, TTM earnings of 2seventy bio Inc (TSVT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 2seventy bio Inc (TSVT) and enter the required number of quantities and click on buy to purchase the shares of 2seventy bio Inc (TSVT).
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. Address: 60 Binney Street, Cambridge, MA, United States, 02142
The CEO & director of Mr. Nick Leschly. is 2seventy bio Inc (TSVT), and CFO & Sr. VP is Mr. Nick Leschly.
There is no promoter pledging in 2seventy bio Inc (TSVT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| 2seventy bio Inc. (TSVT) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.85
|
|
Operating margin(%)
|
-164.48
|
|
Net Margin(%)
|
-8.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 2seventy bio Inc (TSVT) was $0 Mln.
